Literature DB >> 19761834

Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.

Sita Awasthi1, John M Lubinski, Harvey M Friedman.   

Abstract

Herpes simplex virus type 1 (HSV-1) glycoprotein C (gC-1) binds complement component C3b and inhibits complement-mediated immunity. HSV-1 glycoprotein D (gD-1) is a potent immunogen and a candidate antigen for a subunit vaccine. We evaluated whether combined immunization with gD-1 and gC-1 provides better protection against challenge than gD-1 alone based on antibodies to gC-1 preventing HSV-1-mediated immune evasion. IgG purified from mice immunized with gC-1 blocked C3b binding to gC-1 and greatly increased neutralization by gD-1 IgG in the presence of complement. Passive transfer of gC-1 IgG protected complement intact mice against HSV-1 challenge but not C3 knockout mice, indicating that gC-1 antibody activity in vivo is complement-dependent. Immunizing mice with gD-1 and gC-1 provided better protection than gD-1 alone in preventing zosteriform disease and infection of dorsal root ganglia. Therefore, gC-1 immunization prevents HSV-1 evasion from complement and enhances the protection provided by gD-1 immunization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19761834      PMCID: PMC2783579          DOI: 10.1016/j.vaccine.2009.09.017

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  47 in total

1.  Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs.

Authors:  J E Strasser; R L Arnold; C Pachuk; T J Higgins; D I Bernstein
Journal:  J Infect Dis       Date:  2000-10-04       Impact factor: 5.226

2.  Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo.

Authors:  N M Sawtell; R L Thompson; L R Stanberry; D I Bernstein
Journal:  J Infect Dis       Date:  2001-09-10       Impact factor: 5.226

3.  Protective immunity against herpes simplex virus generated by DNA vaccination compared to natural infection.

Authors:  P H Nass; K L Elkins; J P Weir
Journal:  Vaccine       Date:  2001-01-08       Impact factor: 3.641

4.  Herpes simplex virus type 1 latency-associated transcript gene promotes neuronal survival.

Authors:  R L Thompson; N M Sawtell
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs.

Authors:  M Wachsman; M Kulka; C C Smith; L Aurelian
Journal:  Vaccine       Date:  2001-02-28       Impact factor: 3.641

6.  Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection.

Authors:  Manfred Kopf; Brian Abel; Awen Gallimore; Michael Carroll; Martin F Bachmann
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

7.  Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.

Authors:  X J Da Costa; L A Morrison; D M Knipe
Journal:  Virology       Date:  2001-09-30       Impact factor: 3.616

8.  In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor.

Authors:  T Nagashunmugam; J Lubinski; L Wang; L T Goldstein; B S Weeks; P Sundaresan; E H Kang; G Dubin; H M Friedman
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Glycoprotein-D-adjuvant vaccine to prevent genital herpes.

Authors:  Lawrence R Stanberry; Spotswood L Spruance; Anthony L Cunningham; David I Bernstein; Adrian Mindel; Stephen Sacks; Stephen Tyring; Fred Y Aoki; Moncef Slaoui; Martine Denis; Pierre Vandepapeliere; Gary Dubin
Journal:  N Engl J Med       Date:  2002-11-21       Impact factor: 91.245

10.  Herpes simplex virus type 1 evades the effects of antibody and complement in vivo.

Authors:  John M Lubinski; Ming Jiang; Lauren Hook; Yueh Chang; Chad Sarver; Dimitrios Mastellos; John D Lambris; Gary H Cohen; Roselyn J Eisenberg; Harvey M Friedman
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more
  23 in total

Review 1.  Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses.

Authors:  K J Laing; L Dong; J Sidney; A Sette; D M Koelle
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

2.  Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread.

Authors:  Sita Awasthi; Elizabeth E Zumbrun; Huaxin Si; Fushan Wang; Carolyn E Shaw; Michael Cai; John M Lubinski; Shana M Barrett; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compared to immunization with gD alone.

Authors:  Sita Awasthi; John M Lubinski; Carolyn E Shaw; Shana M Barrett; Michael Cai; Fushan Wang; Michael Betts; Susan Kingsley; Daniel J Distefano; John W Balliet; Jessica A Flynn; Danilo R Casimiro; Janine T Bryan; Harvey M Friedman
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

4.  DNA vaccine expressing herpes simplex virus 1 glycoprotein C and D protects mice against herpes simplex keratitis.

Authors:  Li-Li Dong; Ru Tang; Yu-Jia Zhai; Tejsu Malla; Kai Hu
Journal:  Int J Ophthalmol       Date:  2017-11-18       Impact factor: 1.779

5.  A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.

Authors:  Sita Awasthi; Gregory G Mahairas; Carolyn E Shaw; Meei-Li Huang; David M Koelle; Christine Posavad; Lawrence Corey; Harvey M Friedman
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

Review 6.  Recent advances in vaccine development for herpes simplex virus types I and II.

Authors:  Jeffrey L Coleman; Deepak Shukla
Journal:  Hum Vaccin Immunother       Date:  2013-02-26       Impact factor: 3.452

7.  Distinguishing Features of High- and Low-Dose Vaccine against Ocular HSV-1 Infection Correlates with Recognition of Specific HSV-1-Encoded Proteins.

Authors:  Daniel J J Carr; Grzegorz B Gmyrek; Adrian Filiberti; Amanda N Berube; William P Browne; Brett M Gudgel; Virginie H Sjoelund
Journal:  Immunohorizons       Date:  2020-10-09

8.  Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs.

Authors:  Sita Awasthi; John W Balliet; Jessica A Flynn; John M Lubinski; Carolyn E Shaw; Daniel J DiStefano; Michael Cai; Martha Brown; Judith F Smith; Rose Kowalski; Ryan Swoyer; Jennifer Galli; Victoria Copeland; Sandra Rios; Robert C Davidson; Maya Salnikova; Susan Kingsley; Janine Bryan; Danilo R Casimiro; Harvey M Friedman
Journal:  J Virol       Date:  2013-11-27       Impact factor: 5.103

9.  Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine.

Authors:  Sita Awasthi; Robert B Belshe; Harvey M Friedman
Journal:  J Infect Dis       Date:  2014-03-20       Impact factor: 5.226

Review 10.  Understanding and learning from the success of prophylactic human papillomavirus vaccines.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Nat Rev Microbiol       Date:  2012-09-10       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.